Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Rating of “Hold” by Brokerages

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have earned a consensus recommendation of “Hold” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $9.40.

RXRX has been the subject of several research analyst reports. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $10.00 to $11.00 in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. UBS Group set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th.

Insider Buying and Selling

In other news, CFO Ben R. Taylor sold 21,383 shares of Recursion Pharmaceuticals stock in a transaction on Monday, December 29th. The stock was sold at an average price of $4.18, for a total value of $89,380.94. Following the completion of the sale, the chief financial officer directly owned 761,550 shares of the company’s stock, valued at approximately $3,183,279. This trade represents a 2.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Najat Khan sold 124,403 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the transaction, the insider directly owned 611,135 shares in the company, valued at $2,695,105.35. This trade represents a 16.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 585,786 shares of company stock worth $2,558,598 in the last quarter. Insiders own 8.43% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RXRX. TD Waterhouse Canada Inc. lifted its position in Recursion Pharmaceuticals by 64.1% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after purchasing an additional 2,200 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Recursion Pharmaceuticals by 97.2% in the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after buying an additional 4,446 shares during the period. Allworth Financial LP boosted its stake in Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in Recursion Pharmaceuticals during the 2nd quarter worth $51,000. Finally, IFP Advisors Inc grew its holdings in Recursion Pharmaceuticals by 81.5% during the 3rd quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock worth $51,000 after acquiring an additional 4,650 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX opened at $4.66 on Friday. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. The firm has a market cap of $2.42 billion, a PE ratio of -2.59 and a beta of 0.95. Recursion Pharmaceuticals has a 12 month low of $3.79 and a 12 month high of $12.36. The company’s 50-day moving average price is $4.46 and its two-hundred day moving average price is $5.06.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. Recursion Pharmaceuticals’s quarterly revenue was down 80.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.34) earnings per share. On average, equities analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.